Business Practice
CME/CE
Subscribe
BIOSIMILAR APPROVALS
- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilar Oncology Roundup for November 2023—Podcast Edition
On this episode, we discuss the abundance of oncology news from November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.
On this episode, we discuss the abundance of oncology news from November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.
Show notes
- Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?
- Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices
- Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
- Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
- Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study
- Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
- Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim Found in Clinical Studies
- Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Recent Videos
Related Content
